ClinicalTrials.gg
Active, not recruitingNCT04704921ATMOSPHEREUpdated Apr 28, 2026

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

A Phase 2/3 interventional study of ABBV-RGX-314 and ABBV-RGX-314 in AMD, nAMD and Wet Age-related Macular Degeneration, sponsored by AbbVie. Active, not recruiting at 89 sites in United States. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
671
Allocation
Randomized
Ages
50 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 88 studies in Choroidal Neovascularization with a site in United States — 2 open to participants now, 9 under way, 4 of them phase 3. Choroidal Neovascularization · United States.

Enrollment
7th of 77
671 · median 42
Started
2020
with 2 others
Phase 2/3
6 of 88
2 open now
Registered
81st of 88
by date
Lead sponsor
2 of 88
AbbVie

Among the 88 studies in Choroidal Neovascularization with a site in United States, this one is the 7th largest by enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2020, is one of 6 in phase 2/3, and was the 81st registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

2 of the 88 studies in Choroidal Neovascularization with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Choroidal Neovascularization with a site in United States, or all of them as a file.
02

Study summary

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to maintain or prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every 4 to 16 weeks in frequency, to maintain efficacy. Due to the burden of these treatments, patients often experience a decline in vision with reduced frequency of treatment over time.

Read the detailed description

This randomized, partially masked, active-controlled, Phase 2b/3 clinical study will evaluate the efficacy and safety of ABBV-RGX-314 gene therapy in participants with nAMD. The study will evaluate 2 dose levels of ABBV-RGX-314 relative to an active comparator. The primary endpoint of this study is the mean change from baseline in best-corrected visual acuity (BCVA) of ABBV-RGX-314 relative to ranibizumab at Week 54. Approximately 630 participants who meet the inclusion/exclusion criteria, will be enrolled into one of 3 arms.

A bilateral treatment substudy conducted at US sites is an open-label, partially randomized, parallel arm study to evaluate the safety and efficacy of subretinal ABBV-RGX-314 administered bilaterally in participants who have bilateral nAMD. Previously treated crossover participants from the control arm of the main study who crossed over and received ABBV-RGX-314 in the study eye will receive the same ABBV-RGX-314 dose in the contralateral eye (ie, same dose as in the study eye), and newcomers (participants who have not been randomized in an ABBV-RGX-314 study) and untreated crossover participants (ongoing control participants in the main study who have completed Week 54 but have not crossed over to receive ABBV-RGX-314 in the main study) will be randomized in a 2:1 ratio to receive ABBV-RGX-314 Dose 1 or ABBV-RGX-314 Dose 2 in both eyes. Up to 15 participants who qualify for the substudy will be enrolled and followed for a minimum of 50 weeks.

03

Conditions studied

  • AMD
  • nAMD
  • Wet Age-related Macular Degeneration
  • wAMD
  • Wet AMD
  • CNV
  • Neovascular AMD
  • Neovascular Age-related Macular Degeneration
  • Choroidal Neovascularization

Keywords

  • Age-Related Macular Degeneration
  • Neovascular Age-Related Macular Degeneration
  • Macular Degeneration
  • Wet Macular Degeneration
  • Choroidal Neovascularization
  • Retinal Degeneration
  • Retinal Diseases
  • Eye Diseases
  • Ranibizumab
  • Angiogenesis Inhibitors
  • Angiogenesis Modulating Agents
  • Growth Substances
  • Physiological Effects of Drugs
  • Growth Inhibitors
  • Antineoplastic Agents
  • Gene therapy
  • Anti-vascular endothelial grown factory therapy
  • Anti-VEGF therapy
04

Who can participate

Ages eligible
50 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 50 years and ≤ 89 years
  2. An ETDRS BCVA letter score between ≤ 78 and ≥ 40 in the study eye
  3. Diagnosis of subfoveal CNV secondary to AMD in the study eye previously treated with anti-VEGF
  4. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye.
  5. Willing and able to provide written, signed for this study
  6. Participants must have demonstrated a meaningful response to anti-VEGF therapy at study entry

Inclusion Criteria (Bilateral Treatment Substudy)*:

  1. An ETDRS BCVA letter score between ≤ 83 and ≥ 40 in both eyes
  2. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in both eyes
  3. Must be pseudophakic (at least 12 weeks postcataract surgery) in both eyes
  4. Willing and able to provide written, signed informed consent for this study
  5. Newcomers must have active disease in the study eye; crossover participants must have active disease in the eye not treated in the main study

Exclusion criteria

Exclusion Criteria:

  1. CNV or macular edema in the study eye secondary to any causes other than AMD
  2. Subfoveal fibrosis or atrophy in the study eye, as determined by CRC
  3. Any condition in the investigator's opinion that could limit VA improvement in the study eye
  4. Active or history of retinal detachment, or current retinal tear that cannot be treated, in the study eye
  5. Advanced glaucoma or history of secondary glaucoma in the study eye
  6. History of intraocular surgery in the study eye within 12 weeks prior to randomization
  7. History of intravitreal therapy in the study eye, such as intravitreal injection or product, other than anti-VEGF therapy, in the 6 months prior to Screening Visit 1
  8. Prior treatment with gene therapy
  9. Recent myocardial infarction, cerebrovascular accident, or within the past 6 months

Exclusion Criteria (Bilateral Treatment Substudy)*:

  1. CNV or macular edema in either eye secondary to any causes other than AMD
  2. Subfoveal fibrosis or atrophy in either eye
  3. Any condition in the investigator's opinion that could limit VA improvement in either eye
  4. Active or history of retinal detachment, or current retinal tear that cannot be treated in either eye
  5. Advanced glaucoma or history of secondary glaucoma in either eye
  6. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months
  7. History of intraocular surgery in either eye within 12 weeks prior to randomization (Week -2)
  8. History of intravitreal therapy in either eye, such as intravitreal steroid injection or investigational product, other than anti-VEGF therapy, in the 6 months prior to screening
  9. Prior treatment with gene therapy (*) For previously treated crossover participants, criteria apply to the eye not treated in the main study only.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
671 participants (actual)

Study arms

  • Experimental
    ABBV-RGX-314 Dose 1

    ABBV-RGX-314 Dose 1 administered via subretinal delivery one time.

    Genetic: ABBV-RGX-314

  • Experimental
    ABBV-RGX-314 Dose 2

    ABBV-RGX-314 Dose 2 administered via subretinal delivery one time.

    Genetic: ABBV-RGX-314

  • Active comparator
    Control Arm

    Ranibizumab administered via intravitreal injection approximately every 28 days

    Biological: Ranibizumab (LUCENTIS®)

Interventions

  • GeneticABBV-RGX-314

    AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)

    Also known as: surabgene lomparvovec, RGX-314

  • GeneticABBV-RGX-314

    AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)

    Also known as: surabgene lomparvovec, RGX-314

  • 0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days

    Also known as: Ranibizumab (anti-VEGF agent)

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in Best Corrected Visual Acuity (BCVA)

    BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS)

    Time frame: At Week 54

  2. Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEs

    Incidence of ocular AEs and any SAEs

    Time frame: Week 50

Secondary outcomes

  1. Incidences of ocular and overall AEs over 54 weeks

    AEs over 54 weeks

    Time frame: Through Week 54

  2. Incidences of ocular and overall AEs over 98 weeks

    AEs over 98 weeks

    Time frame: Through Week 98

  3. Mean change from baseline in BCVA to Week 98 (ABBV-RGX-314 randomized participants) based on the ETDRS score

    BCVA measured by ETDRS

    Time frame: Week 98

  4. Proportion of participants with worsened BCVA

    Proportion with worsened BCVA

    Time frame: Week 54; Week 98

  5. Proportion of participants with improved BCVA

    Proportion with improved BCVA

    Time frame: Week 54; Week 98

  6. Proportion of participants (1) gaining > 0 letters; (2) losing > 0 letters; maintaining vision (not losing ≥ 15 letters) compared with baseline as per BCVA

    Proportion gaining or losing \> 0 letters based on ETDRS score; proportion maintaining vision

    Time frame: Week 54; Week 98

  7. Mean change from baseline in BCVA for participants who received 0 or more supplemental anti-VEGF injections (ABBV-RGX-314 randomized participants)

    Mean change in BCVA based on ETDRS score for participants who received 0 or more supplemental anti-VEGF injection

    Time frame: Week 54; Week 98

  8. Mean change from Week 54 to Week 98 in BCVA (control arm participants who cross over to ABBV-RGX-314)

    Mean change in BCVA based on ETDRS score

    Time frame: Week 54 to Week 98

  9. Mean change from baseline in CRT as measured by SD-OCT

    Mean change in CRT as measured by SD-OCT

    Time frame: Week 54; (ABBV-RGX-314 randomized participants) Week 98

  10. Mean change from Week 54 to Week 98 in CRT as measured by SD-OCT (control arm participants who cross over to ABBV-RGX-314)

    Mean change in CRT as measured by SD-OCT

    Time frame: from Week 54 to Week 98

  11. Mean change from baseline in CPT as measured by SD-OCT

    Mean change in CPT as measured by SD-OCT

    Time frame: Week 54; (ABBV-RGX-314 randomized participants) Week 98

  12. Mean change from Week 54 to Week 98 in CPT as measured by SD-OCT (control arm participants who cross over to ABBV-RGX-314)

    Mean change in CPT as measured by SD-OCT

    Time frame: from Week 54 to Week 98

  13. Mean number of supplemental anti-VEGF injections from Baseline through Week 54 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 98 (ABBV-RGX-314 randomized participants and control arm participants who cross over to ABBV-RGX-314)

    Mean number of supplemental anti-VEGF injections

    Time frame: Through Week 98

  14. Proportion of participants with 0, 1, 2, and 3 supplemental injections through Week 54 and Week 98 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 98 (control arm participants who cross over to ABBV-RGX-314)

    Proportion of participants with 0, 1, 2, and 3 supplemental injections

    Time frame: Through Week 98

  15. Proportion of participants with ≤ 1, ≤ 2, and ≤ 3 supplemental injections through Week 54 and Week 98 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 98 (control arm participants who cross over to ABBV-RGX-314)

    Proportion of participants with ≤ 1, ≤ 2, and ≤ 3 supplemental injections

    Time frame: Through Week 98

  16. Proportion of participants that received 1 or 2 injections through Week 54 and Week 98 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 98 (control arm participants who cross over to ABBV-RGX-314)

    In the subset of participants who were given supplemental anti-VEGF injections, proportion of participants that received 1 or 2 injections

    Time frame: Through Week 98

  17. Proportion of participants with a reduction of ≥ 50% in anti-VEGF injection annualized rate through Week 54 and Week 98 compared with the prior year (ABBV-RGX-314 randomized participants)

    Proportion of participants with a reduction of ≥ 50% in anti-VEGF injection annualized rate

    Time frame: Through Week 98

  18. Proportion of participants with a reduction of ≥ 75% in anti-VEGF injection annualized rate through Week 54 and Week 98 compared with the prior year (ABBV-RGX-314 randomized participants)

    Proportion of participants with a reduction of ≥ 75% in anti-VEGF injection annualized rate

    Time frame: Through Week 98

  19. Percent reduction in anti-VEGF injection annualized rate compared with the prior year (ABBV-RGX-314 randomized participants)

    Supplemental anti-VEGF injection annualized rate

    Time frame: Through Week 54 and Week 98

  20. Supplemental anti-VEGF injection annualized rate through Week 54 and Week 98 (ABBV-RGX-314 randomized participants)

    Supplemental anti-VEGF injection annualized rate

    Time frame: Through Week 54 and Week 98

  21. Percent reduction in anti-VEGF injection annualized rate after Week 58 through Week 98 relative to the year prior to the study (control arm participants who cross over to ABBV-RGX-314)

    Percent reduction in anti-VEGF injection annualized rate

    Time frame: After Week 58 through Week 98

  22. Supplemental anti-VEGF injection annualized rate after Week 58 through Week 98 (control arm participants who cross over to ABBV-RGX-314)

    Supplemental anti-VEGF injection annualized rate

    Time frame: After Week 58 to Week 98

  23. Time to first supplemental anti-VEGF injection after the Week 2 injection (ABBV-RGX-314 randomized participants)

    Time to first supplemental anti-VEGF injection

    Time frame: Week 98

  24. Time to first supplemental anti-VEGF injection after the Week 58 injection (control arm participants who cross over to ABBV-RGX-314)

    Time to first supplemental anti-VEGF injection

    Time frame: After Week 58 to Week 98

  25. Mean change from baseline in NEI-VFQ-25 (composite score) at Week 54 and (for ABBV-RGX-314 randomized participants and control arm participants who cross over to ABBV-RGX-314) Week 98

    Mean change in NEI VGQ-25 (composite score) at week 54 (control arm participants who cross over to ABBV-RGX-314)

    Time frame: Week 54; Week 98

  26. Mean change from baseline in MacTSQ (composite score) at Week 54 and (for ABBV-RGX-314 randomized participants and control arm participants who cross over to ABBV-RGX-314) Week 98

    Mean change from baseline in MacTSQ (composite score) at week 54 and (control arm participants who cross over to ABBV-RGX-314) at Week 98

    Time frame: Week 54; Week 98

  27. Aqueous ABBV-RGX-314 TP concentrations (ABBV-RGX-314 randomized participants)

    Aqueous ABBV-RGX-314 TP concentration

    Time frame: Wk -2, Wk 14, Wk 26, Wk 38, Wk 54, and Wk 98

  28. Aqueous ABBV-RGX-314 TP concentrations (control arm participants who cross over to ABBV-RGX-314)

    Aqueous ABBV-RGX-314 TP concentration

    Time frame: Wk 54, Wk 66, Wk 78, Wk 90, and Wk 98

  29. Immunogenicity measurements (ABBV-RGX-314 randomized participants)

    Immunogenicity measurements (serum antibodies to AAV8 and serum antibodies to ABBV-RGX-314 TP)

    Time frame: Wk -2, Wk 14, Wk 26, Wk 38, Wk 54, and Wk 98

  30. Immunogenicity measurements (control arm participants who cross over to ABBV-RGX-314)

    Immunogenicity measurements (serum antibodies to AAV8 and serum antibodies to ABBV-RGX-314 TP)

    Time frame: Wk 54, Wk 66, Wk 78, Wk 90, and Wk 98

  31. Bilateral Treatment Substudy: Incidence of nonocular AEs and any AEs of special interest

    Nonocular AEs and AEs of Special interest

    Time frame: Week 50

  32. Bilateral Treatment Substudy: Mean change from Baseline in BCVA at assessed timepoints

    BCVA measured by ETDRS

    Time frame: Through Week 50

  33. Bilateral Treatment Substudy: Mean change from Baseline in CRT at assessed timepoints

    Mean change in CRT as measured by SD-OCT

    Time frame: Through Week 50

  34. Bilateral Treatment Substudy: Supplemental anti-VEGF injection annualized rate

    Supplemental anti-VEGF injection annualized rate

    Time frame: Through Week 50

  35. Bilateral Treatement Substudy: Mean number of supplemental anti-VEGF injections

    Mean supplemental anti-VEGF injections

    Time frame: Through Week 50

  36. Bilateral Treatment Substudy: Proportion of participants with 0, ≤ 1, ≤ 2, and ≤ 3 supplemental anti-VEGF injections

    Proportion of participants with 0, ≤ 1, ≤ 2, and ≤ 3 supplemental anti-VEGF injections

    Time frame: Through Week 50

  37. Bilateral Treatment Substudy: Aqueous humor and serum ABBV-RGX-314 TP concentrations

    Aqueous humor and serum ABBV-RGX-314 TP Concentrations

    Time frame: Wk 26, Wk 34, Wk 50

  38. Bilateral Treatment Substudy: Immunogenicity measurements (serum anti-ABBV-RGX-314 TP antibodies, serum anti-AAV8 antibodies) and enzyme-linked immunospot at assessed time points

    Immunogenicity measurements

    Time frame: Wk 18, Wk 34, Wk 50

07

Study locations

89 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2020 (actual). Primary completion is estimated for Dec 2026, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2021
First posted
Jan 12, 2021
StartActual
Dec 29, 2020
Primary completionEst.
Dec 2026
CompletionEst.
Nov 2027
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04704921
Lead sponsor
AbbVie
Collaborators
REGENXBIO Inc.
Responsible party
Sponsor
First posted
Jan 12, 2021
Start date
Dec 29, 2020
Primary completion
Dec 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Apr 28, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion